01 January 2001
Statin-stimulated nitric oxide release from endothelium.
Lawrence W Dobrucki, Leszek Kalinowski, Iwona T Dobrucki, Tadeusz MalinskiMed Sci Monit 2001; 7(4): BR622-627 :: ID: 421094
Abstract
BACKGROUND: There is increasing evidence that loss of endothelium-derivedNO is a major factor in cardiovascular complication events, and that NO might exert antiatheroscleroticactions. The beneficial effects of HMG CoA reductase inhibitors (statins) therapy in atherosclerosisoutweigh those expected from simply lowering low-density lipoprotein (LDL) cholesterol, and may be relatedto the direct action in the endothelium. Based on these concepts, in the studies described here, theeffect of new statin derivatives on nitric oxide (NO) and superoxide (O2-) release in bovine endothelialcells was tested.MATERIAL AND METHODS: Highly sensitive electrochemical NO and O2--microsensors wereplaced near the surface of endothelial cells, and the concurrent kinetics of NO and O2-- release weremeasured in situ.RESULTS: All tested statins stimulated NO release. The peak concentration of NO afterstimulation with 1 Kmol/l Lovastatin, 1 Kmol/l Atorvastatin, 1 Kmol/l Pravastatin, or 1 Kmol/l Simvastatinwas about 77%, 73%, 72%, and 44% lower, respectively, as compared with the NO peak concentration afterstimulation with 1 Kmol/l calcium ionophore A23187 (receptor-independent agonist). The tested statinsstimulated NO release in a modest way, which resulted in diminishing O2- generation during activationof nitric oxide synthase. Moreover, the kinetics of O2- release after administration of the statins suggestedthat these compounds may also scavenge O2-. The NO/O2- peak concentration ratio after the NOS agonistsadministration was as follows: 7.51 for CaI, 6.56 for Lovastatin, 6.00 for Atorvastatin, 4.17 for Pravastatinand 6.25 for Simvastatin.CONCLUSIONS: The tested statins, i.e. Lovastatin, Atorvastatin, Pravastatinand Simvastatin demonstrate variable potency to enhance the NO/O2- concentration ratio after stimulationof NOS, resulting in an increase of NO bioavailability in endothelial cells.
Keywords: statins, Endothelium, Nitric Oxide, superoxide
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952